BioWorld

Aug. 3, 2009

View Archived Issues

Study Shows Mechanism Behind Allergy-Promoting TH2 Bias

Read More

House Panel Supports 12 Years Data Exclusivity, CER Limits

Read More

Cethromycin Pact Likely Waits as FDA Wants New CAP Trial

Read More

Other News To Note

Read More

Earnings Roundup

Read More

Clinic Roundup

Read More

So Much for Summer Slump: July Financings Keep Pace

While biotech financing lagged in the first quarter, activity picked up in the second quarter, and it looks as if the third quarter is off to a fairly decent start. (BioWorld Today) Read More

FDA Clears Anadys HCV Study; Good Data Could Lure Partner

Read More